Completion and toxicity of induction chemotherapy for metastatic testicular cancer: An updated evaluation of Japanese patients

被引:17
作者
Kawai, Koji [1 ]
Ando, Satoshi [1 ]
Hinotsu, Shiro [1 ]
Oikawa, Takehiro [1 ]
Sekido, Noritoshi [1 ]
Miyanaga, Naoto [1 ]
Shimazui, Toru [1 ]
Akaza, Hideyuki [1 ]
机构
[1] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Urol, Inst Clin Med, Tsukuba, Ibaraki 305, Japan
关键词
testicular cancer; BEP; toxicity; IGCCCG classification;
D O I
10.1093/jjco/hyl053
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Combination of bleomycin, etoposide and cisplatin (BEP) remains the standard chemotherapy for testicular cancer. Since the development of BEP in the 1980s, there has been a considerable advance in supportive therapies, such as granulocyte colony-stimulating-factor and 5-HT3 antagonists. Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care. Methods: The medical records of all 42 testicular cancer patients who received induction chemotherapy at Tsukuba University Hospital were reviewed. Toxicities during the induction chemotherapy were graded according to the Japanese CTCAE v3.0. Results: Dose reduction was needed in only three patients. The subsequent chemotherapy was started at the planned 3 week interval or within 3 days of postponement in 89% of the treatment cycles. The average relative dose intensity (RDI) of bleomycin was 0.95, while that for etoposide and cisplatin was 0.97. There was no death due to toxicity. The most frequent toxicity was leukopenia (grade 3 in 44% and grade 4 in 55%). Post-chemotherapy diffusion capacity was significantly decreased in 30% of patients. Two patients developed bleomycin-induced pneumonitis, but recovered successfully. Sixteen patients received second line or salvage chemotherapy after BEP, subsequently. The overall 5 year cause-specific survival rate was 85%. Conclusion: BEP with high RDIs is acceptable if combined with modern supportive care, with acceptable toxicity profile in most patients.
引用
收藏
页码:425 / 431
页数:7
相关论文
共 28 条
[1]   A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS [J].
BOSL, GJ ;
GELLER, NL ;
BAJORIN, D ;
LEITNER, SP ;
YAGODA, A ;
GOLBEY, RB ;
SCHER, H ;
VOGELZANG, NJ ;
AUMAN, J ;
CAREY, R ;
FAIR, WR ;
HERR, H ;
MORSE, M ;
SOGANI, P ;
WHITMORE, W .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1231-1238
[2]   Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].
Collette, L ;
Sylvester, RJ ;
Stenning, SP ;
Fossa, SD ;
Mead, GM ;
de Wit, R ;
de Mulder, PHM ;
Neymark, N ;
Lallemand, E ;
Kaye, SB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846
[3]  
DINAKARA P, 1970, AM REV RESPIR DIS, V102, P965
[4]   THE ROLE OF MAINTENANCE THERAPY IN DISSEMINATED TESTICULAR CANCER [J].
EINHORN, LH ;
WILLIAMS, SD ;
TRONER, M ;
BIRCH, R ;
GRECO, FA .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (13) :727-731
[5]   Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy [J].
Fosså, SD ;
Kaye, SB ;
Mead, GM ;
Cullen, M ;
de Wit, R ;
Bodrogi, I ;
van Groeningen, CJ ;
De Mulder, PHM ;
Stenning, S ;
Lallemand, E ;
De Prijck, L ;
Collette, L .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :716-724
[6]   Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: A single-institution experience [J].
Gerl, A ;
Clemm, C ;
Schmeller, N ;
Hartenstein, R ;
Lamerz, R ;
Wilmanns, W .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1280-1285
[7]   MANAGEMENT OF MALIGNANT TERATOMA - DOES REFERRAL TO A SPECIALIST UNIT MATTER [J].
HARDING, MJ ;
PAUL, J ;
GILLIS, CR ;
KAYE, SB .
LANCET, 1993, 341 (8851) :999-1002
[8]   POMB/ACE CHEMOTHERAPY IN NONSEMINOMATOUS GERM-CELL TUMORS - OUTCOME AND IMPORTANCE OF DOSE INTENSITY [J].
HUSBAND, DJ ;
GREEN, JA .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (01) :86-91
[9]   Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity [J].
Kawai, K ;
Hinotsu, S ;
Tomobe, M ;
Akaza, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (09) :546-550
[10]   Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer [J].
Kawai, K ;
Miyazaki, J ;
Tsukamoto, S ;
Hinotsu, S ;
Hattori, K ;
Shimazui, T ;
Akaza, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) :127-131